Cargando…
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial
IMPORTANCE: Aurora A kinase (AURKA) activation, related in part to AURKA amplification and variants, is associated with downregulation of estrogen receptor (ER) α expression, endocrine resistance, and implicated in cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) resistance. Alisertib, a selective A...
Autores principales: | Haddad, Tufia C., Suman, Vera J., D’Assoro, Antonino B., Carter, Jodi M., Giridhar, Karthik V., McMenomy, Brendan P., Santo, Katelyn, Mayer, Erica L., Karuturi, Meghan S., Morikawa, Aki, Marcom, P. Kelly, Isaacs, Claudine J., Oh, Sun Young, Clark, Amy S., Mayer, Ingrid A., Keyomarsi, Khandan, Hobday, Timothy J., Peethambaram, Prema P., O’Sullivan, Ciara C., Leon-Ferre, Roberto A., Liu, Minetta C., Ingle, James N., Goetz, Matthew P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999287/ https://www.ncbi.nlm.nih.gov/pubmed/36892847 http://dx.doi.org/10.1001/jamaoncol.2022.7949 |
Ejemplares similares
-
Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017) -
Aurora-A Kinase as a Promising Therapeutic Target in Cancer
por: D’Assoro, Antonino B., et al.
Publicado: (2016) -
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
por: Anders, Carey, et al.
Publicado: (2014) -
Global mapping of urban–rural catchment areas reveals unequal access to services
por: Cattaneo, Andrea, et al.
Publicado: (2021) -
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
por: Angus, Steven P., et al.
Publicado: (2021)